Opendata, web and dolomites

ExitAplasia

Reg-X310: new disruptive medicine for faster exit from aplasia afetr agressive chemotherapy of hematologic malignancies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ExitAplasia project word cloud

Explore the words cloud of the ExitAplasia project. It provides you a very rough idea of what is the project "ExitAplasia" about.

reg    marking    complete    innovation    causes    destruction    faster    2023    stay    leukaemia    10    explore    21    patient    opportunity    substantially    stakeholder    least    portion    acute    paris    changing    breakthrough    health    healthcare    validation    innovative    founded    famous    regeneration    blood    world    speed    solution    aplasia    disrupt    networks    exit    exitaplasia    global    costing    pasteur    clinical    tremendous    game    ce    market    business    days    intravenous    decrease    relation    share    patients    14    red    morbidity    deaths    aggressive    off    length    hospital    turnover    25    speeds    immunity    x310    infection    severe    injection    2027    medicine    actual       dying    cancer    pain    treatment    difficult    acquired    accelerating    deficient    jobs    70    white    with    shortening    99    regstem    french    fragile    chemotherapy    found    room    extremely    risk    company    awarded    commercialisation    spin    recovery    feasibility    sterile    day    toxicological    situation    broaden    death    start    million    cells    reformulate    improvement    triggers    points   

Project "ExitAplasia" data sheet

The following table provides information about the project.

Coordinator
REGSTEM 

Organization address
address: 24 RUE DU FAUBOURG SAINT-JACQUES
city: PARIS
postcode: 75014
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website https://www.regstem.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-11-01   to  2019-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    REGSTEM FR (PARIS) coordinator 50˙000.00

Map

 Project objective

With more than 3.7 million new cases and 1.9 million deaths each year, cancer represents the second most important cause of death and morbidity in Europe; a significant portion is treated by chemotherapy, which triggers the destruction of red and white blood cells: aplasia. This aggressive treatment results in a severe deficient immunity and an extremely fragile health, which causes patients with leukaemia, for example, to stay 21 days at the hospital in a sterile room costing in average €25,000 per day. In this extremely difficult situation, RegStem has found the high-potential solution: the new Reg-X310 medicine which allows faster red and white blood cells regeneration, accelerating exit from aplasia and shortening hospital length of stay of at least 4 days. It is a tremendous improvement in relation to only existing medicine that speeds out aplasia for only one day. This breakthrough innovation will speed up recovery, decrease the risk of dying from a hospital-acquired infection (~7% less), and decrease healthcare cost for around €100,000/patient. Reg-X310 is a game-changing innovation which will substantially improve the treatment of aplasia and disrupt the market. Reg-X310 is being developed by RegStem, a French awarded innovative company, founded as a spin-off of the world-famous Pasteur Institute in Paris. The ExitAplasia project will allow the company to reformulate the Reg-X310 into an intravenous injection and to start the toxicological and clinical validation as well as the CE marking, necessary for the commercialisation in Europe. To accomplish this goal, RegStem will complete a feasibility study to further analyse users’ pain points and actual trends, as well as broaden European key stakeholder networks and explore new business opportunity. RegStem will lead the European and global acute leukaemia market with 10% market share in 2023 and up to 70% before 2027, which will result in €14 and €99 million turnover, and more than 20 new European jobs

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EXITAPLASIA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EXITAPLASIA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ELDICO ED (2019)

ELDICO ED, Shaping the Future of Crystallography - The First Pure Electron Diffraction Equipment for Nano-Crystallography

Read More  

DetectInMen (2019)

Infection detection in human semen

Read More  

Plasmanorg (2019)

Environmental-friendly organic chemical synthesis in plasma reactor

Read More